In Vitro Activity of Gepotidacin against Gram-Negative and Gram-Positive Anaerobes

Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hackel, Meredith A., Karlowsky, James A., Canino, Michele A., Sahm, Daniel F., Scangarella-Oman, Nicole E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846401/
https://www.ncbi.nlm.nih.gov/pubmed/34930028
http://dx.doi.org/10.1128/aac.02165-21
Descripción
Sumario:Gepotidacin (formerly GSK2140944) is a first-in-class triazaacenaphthylene antibacterial currently in phase III clinical trials. When tested against Gram-negative (n = 333) and Gram-positive (n = 225) anaerobes by agar dilution, gepotidacin inhibited 90% of isolates at concentrations of 4 and 2 μg/mL, respectively. Given gepotidacin’s in vitro activity against the anaerobic isolates tested, further study is warranted to better understand the utility of gepotidacin in the treatment of infections caused by clinically relevant anaerobic organisms.

Ejemplares similares